The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infa rct ion and ischaemic stroke , and an increased risk of major and minor bleeding compared with aspirin alone .
According to GRADE criteria , the quality of evidence was moderate for all outcomes except all-cause mortality ( low quality evidence ) and adverse events ( very low quality evidence )
BACKGROUND Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease .
Adding a second antiplatelet drug to aspirin may produce additional benefit for people at high risk and people with established cardiovascular disease .
This is an up date to a previously published review from 2011 .
OBJECTIVES To review the benefit and harm of adding clopidogrel to aspirin therapy for preventing cardiovascular events in people who have coronary disease , ischaemic cerebrovascular disease , peripheral arterial disease , or were at high risk of atherothrombotic disease , but did not have a coronary stent .
The role of clopidogrel and acetylsalicylic acid in the prevention of early-phase graft occlusion due to reactive thrombocytosis after coronary artery bypass operation.
BACKGROUND Reactive thrombocytosis has been reported in 20 % of patients after coronary artery bypass grafting ( CABG ) , a frequency that might be related to the high incidence of thrombotic complications . The present study was planned to investigate the effect of combined treatment with clopidogrel and acetylsalicylic acid ( ASA ) on post-CABG reactive thrombocytosis . METHODS Included in this prospect i ve , r and omized study were 60 patients who underwent CABG operation with a 6-month follow-up . Three study groups were defined : group 1 ( n = 20 ) , a control group of patients who have not developed reactive thrombocytosis after CABG surgery ; group 2 ( n = 20 ) , patients who have developed reactive thrombocytosis and continue taking ASA ( 300 mg/day ) ; and group 3 ( n = 20 ) , patients who have developed reactive thrombocytosis and continue taking ASA ( 300 mg/day ) with the addition of clopidogrel ( 75 mg/day ) . RESULTS The mean ages and sex distributions of the patient groups were similar . There were no significant differences between the groups regarding cardiovascular risk factors , baseline laboratory findings , or intraoperative characteristics . Thrombocytosis disappeared within the first month after the operation in both treatment groups . An evaluation of graft patency in the sixth postoperative month revealed that group 2 had significantly more patients with a " positive " result in the exercise test than group 3 and that group 3 had a lower incidence of graft occlusion than group 2 ( P < .01 ) . CONCLUSIONS Combination antiplatelet therapy with ASA and clopidogrel seems to be more effective than ASA alone for maintaining graft patency in patients with reactive thrombocytosis
The available evidence demonstrates that the use of clopidogrel plus aspirin in people at high risk of cardiovascular disease and people with established cardiovascular disease without a coronary stent is associated with a reduction in the risk of myocardial infa rct ion and ischaemic stroke , and an increased risk of major and minor bleeding compared with aspirin alone .
According to GRADE criteria , the quality of evidence was moderate for all outcomes except all-cause mortality ( low quality evidence ) and adverse events ( very low quality evidence )
BACKGROUND Aspirin is the prophylactic antiplatelet drug of choice for people with cardiovascular disease .
Adding a second antiplatelet drug to aspirin may produce additional benefit for people at high risk and people with established cardiovascular disease .
This is an up date to a previously published review from 2011 .
OBJECTIVES To review the benefit and harm of adding clopidogrel to aspirin therapy for preventing cardiovascular events in people who have coronary disease , ischaemic cerebrovascular disease , peripheral arterial disease , or were at high risk of atherothrombotic disease , but did not have a coronary stent .